A debt-free, cash-rich arm of a global consumer-brand group with a long record of large cash dividends — but profit has stayed broadly flat and recent payouts use up almost all (in one year, more than all) of its earnings.

Reckitt Benckiser (Bangladesh) PLC is the local, listed arm of a well-known global consumer-brand group. It makes and sells branded everyday health, hygiene and household products — the kind of trusted items households buy again and again. On the Dhaka Stock Exchange it is grouped under 'Pharmaceuticals & Chemicals', and it has traded there since 1987 — nearly four decades of public history.

It is very small by share count: only about 0.47 crore shares (around 47 lakh), each with a face value of 10 taka. Paid-up capital is just 4.72 crore taka, but it sits on accumulated reserves of about 85.3 crore taka — far larger than its share capital.

Ownership is highly concentrated: sponsors and directors hold 82.96% of the shares, institutions about 6.8%, the government about 3.77%, and only about 6.46% is in ordinary public hands. That large sponsor stake is typical of a company that is the local arm of a bigger parent, and it means relatively few shares change hands in the market.

The company earns its money by selling branded consumer products to households across Bangladesh — everyday, repeat purchases rather than big one-off buys. That kind of demand tends to be steady from year to year.

Its yearly sales have climbed slowly: about 494.2 crore taka in 2021, 496.9 crore in 2022, 528.2 crore in 2023, and 545.9 crore in 2024. Out of those sales it keeps a solid operating profit — around 115.3 crore taka in 2021, 98.8 crore in 2022, 117.0 crore in 2023, and 110.8 crore in 2024.

Because the brands are trusted and bought repeatedly, revenue holds fairly steady rather than swinging wildly — the hallmark of a consumer-goods business. It also spends only modestly on new equipment, with capital spending of about 11.4 to 16.7 crore taka a year over 2021–2024.

The company makes a real profit every year. Net profit was 73.9 crore taka in 2020, 80.8 crore in 2021, 65.9 crore in 2022, 82.0 crore in 2023, 75.2 crore in 2024, and 81.7 crore in 2025.

Profit per share followed the same up-and-down path: 156.38 taka in 2020, 171.03 in 2021, 139.5 in 2022, 173.65 in 2023, 159.17 in 2024, and 172.93 in 2025. Both the profit and the profit-per-share rose only about 11% across the whole 2020–2025 stretch.

So earnings are reliable but not growing much — they wobble within a range, with 2022 the soft spot and no clear upward march. This is a steady earner, not a fast grower.

This is one of the safest balance sheets around. The company reports no bank loans at all (total loan 0). Even its small other borrowings shrank — total debt of about 15.4 crore taka in 2021 and 15.0 crore in 2022, falling to 3.1 crore in 2023 and 6.93 crore in 2024 — a rounding error next to its own money (debt was just 0.16, 0.18, 0.03 and 0.04 of equity in those years).

It also holds a large cash pile: about 162.9 crore taka in 2021, 197.8 crore in 2022, 291.9 crore in 2023, and 220.3 crore in 2024. Its own money (equity) grew from about 94.8 crore in 2021 to 165.7 crore in 2024, and reserves of about 85.3 crore taka give it a thick cushion to ride out a bad year.

One thing to watch: the cash the business actually generates was strong for years — operating cash flow of 63.7 crore taka in 2021, 128.4 crore in 2022, and 117.0 crore in 2023 — but it collapsed to just 3.7 crore in 2024. One weak year isn't a crisis for a debt-free, cash-rich company, but it's worth keeping an eye on whether it recovers.

Dividends are the main attraction here — and also where the main caution sits. It has paid a cash dividend every year: 1400% of face value in 2020, 1650% in 2021, 980% in 2022, 550% in 2023, a very large 3330% in 2024, and 1730% for 2025. On the 10 taka face value, those are cash payments of 140, 165, 98, 55, 333, and 173 taka per share.

The catch is how much of profit this eats. In 2025 the company earned about 172.93 taka per share and paid 173 taka — practically its entire year's profit. In 2024 it paid 333 taka while earning only 159.17 taka — more than it made that year, funded from past reserves and cash.

So it is a strong, reliable dividend payer, but recent dividends are at or above what it earns and may not stay this high year after year. The amount also swings a lot — from 55 taka in 2023 to 333 taka in 2024 to 173 taka in 2025 — so the income isn't a steady, predictable figure even though it's paid every year.

Its real edge is being the local arm of a strong global consumer brand — trusted names households buy over and over, which keeps sales steady and lets the company earn a high profit on the money invested in it.

Turning the owners' money into profit, it stands out: it earns a high return on its own equity, stronger than most companies in its 'Pharmaceuticals & Chemicals' group, with one big rival — Marico Bangladesh — clearly doing even better on that measure. It is also unusually safe: no bank loans and plenty of cash, which few peers match.

The flip side is growth. A couple of smaller sector peers — for example Navana Pharmaceuticals — grew their profit faster in the latest year, while Reckitt's profits have mostly moved sideways. So the edge here is about quality, brand trust and safety, not fast expansion.

• Rock-solid finances. No bank loans at all, and its small other debt fell to about 6.93 crore taka in 2024 — a tiny fraction of its own money — so it does not depend on lenders.
• Big, every-year cash dividends. It has paid a cash dividend every year, including 333 taka per share in 2024 and 173 taka for 2025 — a strong draw for income-focused holders.
• A trusted global brand. As the local arm of a well-known consumer-brand group, it sells everyday products households buy repeatedly, giving steady sales of about 494.2 to 545.9 crore taka over 2021–2024.
• High profitability and a big cash pile. It earns a high return on the money invested in it, held cash of about 220.3 crore taka in 2024, and keeps reserves of about 85.3 crore.
• Tightly held. Sponsors and directors own 82.96%, showing the parent group's strong, long-term commitment.

• Barely any growth. Net profit and profit per share each rose only about 11% over 2020–2025, and dipped in some years — this is not a fast grower.
• Dividends eat almost all the profit. In 2025 it paid 173 taka per share while earning 172.93; in 2024 it paid 333 taka while earning only 159.17 — payouts at or above earnings can't continue forever without drawing down cash.
• A cash-flow wobble. Operating cash flow crashed from 117.0 crore taka in 2023 to just 3.7 crore in 2024 — worth watching to see if it bounces back.
• Very few shares trade freely. With only about 0.47 crore shares and 82.96% held by sponsors, very little floats in the market, so it can be hard to buy or sell sizeable amounts.
• Lumpy dividend. The payout jumped from 55 taka in 2023 to 333 taka in 2024 to 173 taka in 2025 — the income size is unpredictable even though it's paid every year.

On the numbers, Reckitt Benckiser (Bangladesh) is a high-quality, low-risk business: no debt, a big cash pile, a trusted global brand, and a cash dividend paid every single year. For an investor who wants a financially solid, dividend-oriented, blue-chip-style holding and plans to hold patiently, it has a lot going for it.

The trade-offs are real. Profit has barely grown over six years, so don't expect the business to expand quickly. And recent dividends have used up almost all — in 2024, more than all — of a year's profit, so the income may come down from these very high levels; the sharp drop in 2024's operating cash flow is also worth watching.

It suits steady, long-term, income-minded investors more than growth-seekers or active traders who need easy liquidity. Whether today's price is reasonable is shown in the live value estimate beside this report.